We are live on ! Find out more
CASI

CASI Pharmaceuticals
CASI

Delisted

CASI was delisted on the 25th of February, 2026.

Back to rankings

58 hedge funds and large institutions have $46M invested in CASI Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0.57% less ownership

Funds ownership: 3.34% → 2.77% (-0.57%)

15% less funds holding

Funds holding: 68 → 58 (-10)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

36% less capital invested

Capital invested by funds: $72.3M → $46M (-$26.3M)

50% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 20

Holders
58
Holders Change
-10
Holders Change %
-14.71%
% of All Funds
1.02%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
10
Increased
13
Reduced
18
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$988K
2
Marshall Wace
Marshall Wace
United Kingdom
+$985K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$326K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$314K
5
CSS
Cubist Systematic Strategies
Connecticut
+$267K

Top Sellers

1
CCM
Consonance Capital Management
New York
-$11.8M
2
Charles Schwab
Charles Schwab
California
-$475K
3
Millennium Management
Millennium Management
New York
-$403K
4
TEE
Tibra Equities Europe
United Kingdom
-$335K
5
JP Morgan Chase
JP Morgan Chase
New York
-$249K
Name Holding Trade Value Shares
Change 		Change in
Stake
FF
76
FourThought Financial
Florida
– -$1K -4 Closed
1 2 3
4

CASI Hedge Fund Activity: Q3 2021 in Review

58 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q3 2021, worth a combined $46M — down 36% from $72.3M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of CASI and 10 opened new positions — a net loss of 10 holders — while 18 trimmed existing stakes and 13 added.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $988K. The largest seller was Consonance Capital Management, cutting an estimated $11.8M.

  • 58 institutional investors held CASI Pharmaceuticals (CASI) as of Q3 2021, down from 68 in Q2 2021.
  • Funds reported $46M of CASI Pharmaceuticals stock for Q3 2021, down 36% quarter-over-quarter.
  • 10 funds opened new CASI Pharmaceuticals positions in Q3 2021 and 20 closed out, a net change of -10 holders.
  • The largest CASI Pharmaceuticals buyer in Q3 2021 was Jacobs Levy Equity Management, an estimated $988K added.
  • The largest CASI Pharmaceuticals seller in Q3 2021 was Consonance Capital Management, an estimated $11.8M sold.

Based on aggregated 13F filings for Q3 2021.